Literature DB >> 10997618

Adrenomedullary function and its regulation in obesity.

G Del Rio1.   

Abstract

Sympathoadrenal system (SAS) represents a major contributor to body homeostasis, regulating blood pressure heart rate, energy balance and intermediary metabolism. Thus, it is not unexpected that in last decades a consistent literature has been focused on the possible role of sympathoadrenal system in the pathogenesis of human obesity. There are, however, many factors confounding comparison of sympathoadrenal system activity between lean and obese subjects. Among these, one should be aware that SAS should be functionally separated into sympathetic nervous system (SNS) and adrenal medulla (AM), and that each of these two systems can be activated independently from the other by distinct physiological stimuli; this phenomenon in fact underlies the discordant pattern of findings for adrenomedullary and sympathetic activity in human obesity. While, in fact, obese subjects often display an increased basal SNS activity, there are numerous reports of blunted AM function in obese. Recent evidence suggests that this reduced adrenaline secretion is an acquired feature of human obesity, a finding that fits in well with the hypothesis that hormonal milieu, particularly sex steroids and cortisol, plays a role in the determination of blunted AM activity. Catecholamines have been recently demonstrated to play a role also in the regulation of whole energy balance. Adrenaline in fact acutely reduces both leptin mRNA as well as circulating leptin in human obese subjects, suggesting that catecholamines may influence the cross-talk between energy stores and the centrally mediated modulation of food intake. In summary, the study of adrenomedullary function and of possible mechanisms of its disturbances in human obesity, appears of great interest, and surely deserves further investigations.

Entities:  

Mesh:

Year:  2000        PMID: 10997618     DOI: 10.1038/sj.ijo.0801287

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  8 in total

1.  Obesity and catecholamine responses to maximal exercise in adolescent girls.

Authors:  H Zouhal; G Jabbour; H Youssef; A Flaa; E Moussa; C Groussard; C Jacob
Journal:  Eur J Appl Physiol       Date:  2010-05-08       Impact factor: 3.078

2.  Shift work and subfecundity: a causal link or an artefact?

Authors:  J L Zhu; N H Hjollund; H Boggild; J Olsen
Journal:  Occup Environ Med       Date:  2003-09       Impact factor: 4.402

Review 3.  Interactions of metabolic hormones, adipose tissue and exercise.

Authors:  Robert G McMurray; Anthony C Hackney
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

4.  The clinical biochemistry of obesity.

Authors:  Ken A Sikaris
Journal:  Clin Biochem Rev       Date:  2004-08

5.  Adrenal medullary dysfunction as a feature of obesity.

Authors:  M Reimann; N Qin; M Gruber; S R Bornstein; C Kirschbaum; T Ziemssen; G Eisenhofer
Journal:  Int J Obes (Lond)       Date:  2017-02-06       Impact factor: 5.095

Review 6.  Catecholamines and obesity: effects of exercise and training.

Authors:  Hassane Zouhal; Sophie Lemoine-Morel; Marie-Eve Mathieu; Gretchen A Casazza; Georges Jabbour
Journal:  Sports Med       Date:  2013-07       Impact factor: 11.136

7.  Evaluation of Normal Adrenal Gland Volume and Morphometry and Relationship with Waist Circumference in an Adult Population Using Multidetector Computed Tomography.

Authors:  Enes Gurun; Mustafa Kaya; Kubra Hasimoglu Gurun
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-09-24

8.  Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours.

Authors:  Yaxin An; Manja Reimann; Jimmy Masjkur; Katharina Langton; Mirko Peitzsch; Timo Deutschbein; Martin Fassnacht; Natalie Rogowski-Lehmann; Felix Beuschlein; Stephanie Fliedner; Anthony Stell; Aleksander Prejbisz; Andrzej Januszewicz; Jacques Lenders; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Int J Obes (Lond)       Date:  2018-03-03       Impact factor: 5.095

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.